The Official Journal of the Turkish Society Of Clinical Microbiology and Infectious Diseases (KLİMİK)


Filter Newest Oldest Showing 1-11 of 11 results
Review Article / VOLUME 6, ISSUE 2, JUNE 2024

Discontinuation of Nucleos(t)ide Analogues in HBeAg Negative Chronic Hepatitis B Patients: Risks and Benefits

Pınar Korkmaz and Neşe Demirtürk

Chronic hepatitis B (CHB) remains a major threat to global public health, affecting 296 million people worldwide. CHB increases the risk of cirrhosis, liver failure and hepatocellular carcinoma, causing liver-related morbidity and mortality. All these risks can be prevented with antiviral treatment. Although there is no curative treatment for CHB today the virus can be effectively controlled with existing (...) Read More

Original Article / VOLUME 6, ISSUE 1, MARCH 2024

Predictors of Significant Histological Hepatic Abnormality in Treatment-Naive Patients Infected with HBeAg-Negative Chronic Hepatitis B

Gülşah Tunçer and others

Chronic hepatitis B (CHB)  infection is a global health problem that the World Health Organization (WHO) reported 296 million individuals diagnosed with CHB, and 820,000 died worldwide in 2019. In our country, as per the Türkiye Viral Hepatitis Prevention and Control Program for 2018-2023, there have been 3.3 million patients with CHB infection in Türkiye. Read More

Review Article / VOLUME 5, ISSUE 4, DECEMBER 2023

New Treatment Options in Chronic Hepatitis B: How Close Are We to Cure?

Pınar Korkmaz and others

Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease worldwide. HBV-infected patients are at risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) for life. Today, pegylated interferon (Peg-IFN) and nucleos(t)ide analogues (NAs) are used in the treatment of patients with chronic hepatitis B (CHB). Both treatment options have limitations. Read More

Original Article / VOLUME 5, ISSUE 4, DECEMBER 2023

How Successful Are APRI and FIB-4 Scores in Predicting Liver Fibrosis in Chronic Hepatitis B Patients?

Deniz Gür-Altunay and Pınar Yürük-Atasoy

Hepatitis B virus (HBV) infection is an important public health problem worldwide. It is the most important cause of acute and chronic liver disease and hepatocellular cancer. Hepatitis B infection is diagnosed by the detection of HBsAg in the serum or plasma. Chronic hepatitis B (CHB) infection is defined as the persistence of (...) Read More

Original Article / VOLUME 5, ISSUE 2, JUNE 2023

Change in Rates of HBsAg and Anti-HBs in Şırnak 20 Years After Introduction of Hepatitis B Vaccine into Routine Infant Immunization Program

Meyha Şahin and Meltem Yazla

Chronic hepatitis B virus (HBV) infection is a serious public health problem affecting 257 million people worldwide (3.5% of the world population), according to World Health Statistics 2015 by the World Health Organization (WHO). In Turkey, approximately 3.3 million people (4.57% of the population) are considered HBsAg (hepatitis B surface antigen) positive (...) Read More

Case Report / VOLUME 4, ISSUE 3, SEPTEMBER 2022

An Unusual Cause of Acute Isolated Hepatitis in a Cancer Patient Post-COVID Pneumonia: HSV-2

Türkkan Öztürk-Kaygusuz and others

Herpes simplex virus (HSV) is a double-stranded DNA alphaherpesvirus. HSV-1 is a common human pathogen infecting more than 60% of the world’s population, and HSV-2 infects about 11% of the population. HSV rarely causes visceral organ infections. However, some of these disseminated infections are life-threatening. Hepatitis due to HSV is a rare (...) Read More

Commentary / VOLUME 4, ISSUE 2, JUNE 2022

Pediatric Cases with Acute Severe Hepatitis of Unknown Origin: Summary of Special Session “Acute Severe Hepatitis of Unknown Etiology in Children” at the 32nd ECCMID in Lisbon, Portugal

Gülşen Özkaya Şahin and others

Following the increase in number of pediatric cases with acute severe hepatitis of unknown etiology (ASHep-UE), in collaboration with European Center for Disease Control (ECDC) and the United Kingdom Health Security Agency (UKHSA), a special late breaking session “Hepatitis of unknown origin” was (...) Read More

Original Article / VOLUME 4, ISSUE 1, MARCH 2022

Evaluation of Tenofovir Disoproxil Fumarate Treatment in Patients with Chronic Hepatitis B

Petek Konya and Neşe Demirtürk

Chronic hepatitis B (CHB) is one of the major causes of chronic liver diseases worldwide. Around 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year and more than 820 thousand people losing their life because of hepatitis B virus (HBV) related complications.  Chronic HBV (...) Read More

Original Article / VOLUME 1, ISSUE 3, DECEMBER 2019

The Seroprevalence of Anti-Hepatitis E IgG Antibodies in Blood Donors in The Greater Romagna Area, Italy

Anna Pierro and others

Hepatitis E virus (HEV) represents one of the major cause of acute viral hepatitis worldwide, according to the WHO, one-third of the world population has been exposed to HEV. In Europe, there is extensive evidence indicating that HEV is prevalently transmitted by the ingestion of pork and wild boar raw meat, however, [...] Read More

Original Article / VOLUME 1, ISSUE 2, AUGUST 2019

Ombitasvir/ Paritaprevir/ Ritonavir + Ribavirin Combination Therapy in Hepatitis C Virus Infected Patients with Genotype 4 in Real-life Practice: A Multicentre Experience

Bilgehan Aygen and others

About 170-200 million people are known to be infected with the hepatitis C virus (HCV) worldwide. Chronic hepatitis C (CHC) infection carries risks of hepatic fibrosis, cirrhosis, portal hypertension, liver failure, and hepatocellular carcinoma (HCC) (1-4). Chronic HCV infection is an important health problem in Turkey (5-10). In Turkey, among HCV infections, genotype 1b was reported to be the most common one (90%), while [...] Read More